Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.56 |
| ▸ | LPL | P06858 | 12/20 | 0.56 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15213736 | 1.00 | LIPG (0.56) | LIPGLPLP4HBDGAT1PDK2 | |
| SCHEMBL23593183 | 1.00 | LIPG (0.56) | LIPGLPLP4HBDGAT1PDK2 | |
| SCHEMBL30288155 | 1.00 | LIPG (0.56) | LIPGLPLP4HBDGAT1PDK2 | |
| SCHEMBL19554369 | 1.00 | LIPG (0.56) | LIPGLPLP4HBDGAT1PDK2 | |
| SCHEMBL23485894 | 1.00 | LIPG (0.56) | LIPGLPLP4HBDGAT1PDK2 | |
| SCHEMBL15906974 | 0.97 | LIPG (0.51) | LIPGLPLP4HBDGAT1PDK2 | |
| SCHEMBL23592373 | 0.95 | LIPG (0.56) | LIPGLPLP4HBDGAT1PDK2 | |
| SCHEMBL15803118 | 0.94 | LIPG (0.46) | LIPGLPLP4HBPDK2CA1 | |
| SCHEMBL31576189 | 0.94 | LIPG (0.46) | LIPGLPLP4HBPDK2CA1 | |
| SCHEMBL18016693 | 0.94 | LPL (0.44) | LIPGLPLP4HBPDK2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260107684-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER | LT MATERIALS CO LTD (KR) | 2026-04-16 | — | — | US | disclosed |
| EP-4423064-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423063-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423065-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423073-A2 | COMPOUNDS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023072976-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023072977-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023072975-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023027336-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 엘티소재주식회사 | 2023-03-02 | — | — | WO | disclosed |
| WO-2023281126-A2 | COMPOUNDS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-01-12 | — | — | WO | disclosed |
| EP-4066289-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2022-10-05 | — | — | EP | disclosed |
| EP-4041709-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2022-08-17 | — | — | EP | disclosed |
| CN-114730843-A | Compounds for electronic devices | 默克专利有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114466842-A | Compounds for electronic devices | 默克专利有限公司 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260107684-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER | C1S, CRY1, CYP1A1 | LIPG 4542/4885LPL 3870/4885P4HB 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.